Table 2.
Numbers of drugs used by patients with suspected DI-ILD subdivided into those possessing a CYP2D6, CYPC9, and/or CYP2C19 polymorphism, with or without a drug metabolized by an affected metabolic pathway, and those without any of the tested polymorphisms
| Cohort of cases with suspected drug-induced interstitial lung diseases, n = 467 | |||
|---|---|---|---|
| CYP2D6/2C9/2C19 polymorphism; use of drug(s) by an affected metabolic pathway, n = 369 (79.0) | CYP2D6/2C9/2C19 polymorphism; no use of a drug by an affected metabolic pathway, n = 17 (3.6) | No polymorphism; use of drug(s) by a tested not-affected metabolic pathway, n = 81 (17.4) | |
| ≥ 3 drugs/PM | 175 (37.5) | 1 (0.2) | 40 (8.6) |
| ≥ 2 drugs/PM | 280 (60.0) | 5 (1.1) | 67 (14.3) |
| 1 drug | 89 (19.1) | 10 (2.1) | 14 (3.0) |
| 0 drugs | 0 | 2 (0.4) | 0 |
| Nitrofurantoin | 66 (14.1) | 8 (1.7) | 21 (4.5) |
| CYP2D6 polymorphism | 230 (62.3) | 11 (64.7) | 0 |
| ≥ 3 drugs | 89 (24.1) | 0 | 26 (32.1) |
| ≥ 2 drugs | 152 (41.2) | 0 | 27 (33.3) |
| 1 drug | 65 (17.6) | 0 | 21 (25.9) |
| 0 drugs | 13 (3.5) | 11 (64.7) | 7 (8.6) |
| CYP2C9 polymorphism | 169 (45.8) | 6 (35.3) | 0 |
| ≥ 3 drugs | 62 (16.8) | 0 | 21 (25.9) |
| ≥ 2 drugs | 115 (31.2) | 0 | 34 (42.0) |
| 1 drug | 49 (13.3) | 0 | 21 (25.9) |
| 0 drugs | 5 (1.4) | 6 (35.3) | 5 (6.2) |
| CYP2C19 polymorphism | 158 (42.8) | 5 (29.4) | 0 |
| ≥ 3 drugs | 63 (17.0) | 0 | 23 (28.4) |
| ≥ 2 drugs | 100 (27.1) | 0 | 23 (28.4) |
| 1 drug | 52 (14.1) | 0 | 27 (33.3) |
| 0 drugs | 6 (1.6) | 5 (29.4) | 7 (8.7) |
Data are expressed as absolute numbers, with percentage in parentheses
CYP cytochrome P450, PM poor metabolizer